GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx, trading on NASDAQ under the symbol WGS, is a leading provider of high‐quality genetic testing services with a focus on rare and ultra‐rare inherited conditions. Since its founding in 2000, the company has pioneered the use of whole exome sequencing, chromosomal microarrays and targeted gene panels to deliver comprehensive diagnostic insights. GeneDx’s laboratory in Gaithersburg, Maryland, is CLIA‐certified and CAP‐accredited, reflecting its commitment to rigorous quality standards and clinical utility.

The firm’s core offerings span a broad range of clinical specialties, including neurology, cardiology, oncology, immunology and pediatric medicine. GeneDx’s rare disease testing service utilizes advanced next‐generation sequencing technologies to analyze thousands of genes simultaneously, supporting earlier and more accurate diagnoses. In addition to diagnostic tests, the company provides pharmacogenomic screening, reproductive carrier screening and noninvasive prenatal screening, enabling physicians and patients to make informed treatment and family planning decisions.

GeneDx serves a global clientele, partnering with clinicians, hospitals and academic centers in the United States, Europe, Asia and beyond. Through collaborative relationships with specialty laboratories and research institutions, the company extends its testing capabilities to more than 90 countries. Over the years, GeneDx has expanded its international footprint via strategic alliances and participation in multi‐center research initiatives, reinforcing its reputation as a trusted partner in precision medicine and translational genomics.

The company is guided by a leadership team of seasoned experts in molecular diagnostics, clinical laboratory operations and health care strategy. Leveraging decades of combined experience, the executive management continues to drive innovation in genomic medicine while maintaining operational excellence. As part of the BioReference Laboratories family, GeneDx benefits from shared resources in regulatory compliance, information technology and business development, positioning it for sustained growth in the rapidly evolving field of genetic testing.

Key Stats

• Today's Range: $82.12 to $88.48
• 50-Day Range: $56.44 to $116.97
• 52-Week Range: $25.32 to $117.75
• Volume: 338,826 shs
• Average Volume: 816,418 shs
• Market Capitalization: $2.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $90.13
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 47% of companies evaluated by MarketBeat, and ranked 606th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

GeneDx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 115.46%

Earnings Growth

Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is -59.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is -59.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 9.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.03% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeneDx has recently increased by 3.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.03% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeneDx has recently increased by 3.02%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.48

News Sentiment

GeneDx has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for GeneDx this week, compared to 9 articles on an average week.

Search Interest

Only 4 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

MarketBeat Follows

2 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have sold 23.56% more of their company's stock than they have bought. Specifically, they have bought $5,601,000.00 in company stock and sold $6,920,533.00 in company stock.

Percentage Held by Insiders

29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WGS Stock Analysis - Frequently Asked Questions

How have WGS shares performed this year?

GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS shares have increased by 9.9% and is now trading at $84.49.

How were GeneDx's earnings last quarter?

GeneDx Holdings Corp. (NASDAQ:WGS) posted its earnings results on Wednesday, April, 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. The business earned $87.12 million during the quarter, compared to analyst estimates of $79.90 million. GeneDx had a negative net margin of 11.69% and a positive trailing twelve-month return on equity of 10.17%.
Read the conference call transcript.

When did GeneDx's stock split?

GeneDx's stock reverse split before market open on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of GeneDx?

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GeneDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: sema4.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $90.13
• High Stock Price Target: $118.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +5.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 88.39
• P/E Growth: N/A
• Net Income: -$52.29 million
• Net Margins: -11.69%
• Pretax Margin: -11.63%
• Return on Equity: 10.17%
• Return on Assets: 5.51%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.25
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: $330.14 million
• Price / Sales: 7.41
• Cash Flow: $0.96 per share
• Price / Cash Flow: 89.53
• Book Value: $8.75 per share
• Price / Book: 9.80

Miscellaneous

• Outstanding Shares: 28,533,000
• Free Float: 20,087,000
• Market Cap: $2.45 billion
• Optionable: Optionable
• Beta: 2.01